TransMedics provides end-to-end technology & expert clinical service solutions that maximize heart & lung transplant volume, clinical outcomes and reduce learning curves.

TransMedics was founded to address the growing need for healthier organs for transplantation. We are focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs.

The TransMedics Organ Care System (OCS) is a fully portable, multi-organ, normothermic preservation and assessment technology that mirrors human physiology, minimizes ischemia, and provides the ability to optimize the organ during transport.

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the Organ Care System, or the OCS, to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for ...

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

Explore the job openings currently available at TransMedics. New positions will continue to become available as we expand our team and increase our potential to preserve more organs and save more lives.

Coming in early 2025, OCS Connect™ will provide full visibility for our transplant center partners, with secure access to the recovering TransMedics NOP team supporting your mission, including key status and resource logistics details.

Learn more about OCS Liver, including clinical study for utilized and untilized donor livers. OCS is designed to enable surgeons to transplant more organs from the available donor pool and to achieve better procedural outcomes.

Sep 30, 2024 · ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. (" TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024.

Learn about the role TransMedics OCS played in Silvano’s successful transplant surgery for pulmonary fibrosis.